Day: September 20, 2024

Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024

Written by Customer Service on September 20, 2024. Posted in Earnings Releases And Operating Results.

JI’AN, Jiangxi, China, Sept. 20, 2024 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company,” “we,” “our” and “us”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of fiscal year 2024 ended March 31, 2024. Mr. Gang Lai, Chairman of the Board of Directors and CEO of Universe Pharmaceuticals INC, commented, “During the first six months of fiscal year 2024, we navigated business uncertainties and adjusted our business strategy to offset the impact of the global economic slowdown. As a result, we generated $12.9 million in revenue for the six months ended March 31, 2024, lower than the $18.5 million revenue generated in the same period of last year. We made considerable efforts to implement our growth strategies during this challenging...

Mondelēz International to Acquire Evirth, a China Leader in Fast-Growing Cakes and Pastries

Written by Customer Service on September 20, 2024. Posted in Mergers And Acquisitions.

Significantly expands Mondelēz investment in a China category leader for frozen-to-chilled cakes and pastries Meets rising demand for fresh, premium offerings – especially among younger consumers in top-tier cities Builds upon existing strategic partnership to launch new Oreo and Philadelphia branded product innovations and expand distribution CHICAGO, Sept. 20, 2024 (GLOBE NEWSWIRE) — Mondelēz International, Inc. (Nasdaq: MDLZ) today announced that it has signed an agreement to acquire a significant majority stake in Evirth, a leading manufacturer of cakes and pastries in China, subject to customary closing conditions, including regulatory approval. The move represents an important step forward in Mondelēz’s strategy to accelerate growth in the cakes and pastries category – a core focus for the company, alongside chocolate and...

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Written by Customer Service on September 20, 2024. Posted in Earnings Releases And Operating Results.

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update. “Our fiscal year 2024 was a transformational year for iBio, as we’ve solidified our business and financial position as a next-generation antibody company with a machine-learning-enabled platform for designing and developing difficult-to-drug therapeutics,” said CEO and Chief Scientific Officer Martin Brenner, Ph.D., DVM. “We made significant progress entering the fast-growing cardiometabolic and obesity space with our collaboration with AstralBio and strengthened our financial position by eliminating our debt associated with the facility and closing a fully subscribed financing including...

Gaxos.ai Inc. Announces Exercise of Warrants for $3.24 Million Gross Proceeds

Written by Customer Service on September 20, 2024. Posted in Public Companies.

Roseland, NJ, Sept. 20, 2024 (GLOBE NEWSWIRE) — Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 1,256,734 shares of its common stock originally issued in March 2024 and having an original exercise price of $5.50 per share, at a reduced exercise price of $2.58 per share. The issuance and sale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-3 (File No. 333-278513). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the existing...

Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. Announce Business Combination to Create Nasdaq-Listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity

Written by Customer Service on September 20, 2024. Posted in Public Companies.

– Longevity Biomedical, Inc. is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions to become a leading provider of longevity-related products and services designed to increase the health span for the rapidly growing global aging population. – Late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair. – Near-term clinical milestones include Phase 3 start for LBI-201 for Ischemic stroke, Phase 2 data for LBI-101 for soft-tissue reconstruction, and Phase 2 start for LBI-001 in retinal vein occlusion. – Seasoned management team of medtech and biopharmaceutical veterans with track record of acquiring, developing, and commercializing...

DIRTT Announces Results of Special Meeting of Shareholders

Written by Customer Service on September 20, 2024. Posted in Public Companies.

CALGARY, Alberta, Sept. 20, 2024 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (“DIRTT”) (TSX: DRT) (OTC: DRTTF) announced today the results of its special meeting of shareholders held on September 20, 2024 (the “Shareholders Meeting”). At the Shareholders Meeting, shareholders of DIRTT voted in favour of ratifying, confirming and approving the Amended and Restated Shareholder Rights Plan Agreement dated as of August 2, 2024, between DIRTT and Computershare Trust Company of Canada, as Rights Agent (the “Rights Plan”). The detailed results of the vote on the Rights Plan are as follows: RATIFICATION, CONFIRMATION AND APPROVAL OF THE RIGHTS PLAN VOTES FOR % FOR VOTES AGAINST % AGAINST 148,572,128 92.27 12,452,171 7.73 The Rights Plan was also approved by disinterested shareholders (in accordance with the rules of the...

Welltec Q3 2024 Interim Report and Investor Conference Call Announcement

Written by Customer Service on September 20, 2024. Posted in Earnings Releases And Operating Results.

Q3 2024 Interim Report and Investor Conference Call AnnouncementWelltec® will disclose its Q3 2024 Interim Report and will discuss the results during an investor conference call to be held Monday, November 11th, 2024, at 5 pm CET. The conference call will be available only to current and prospective bond holders, broker dealers, and securities analysts, and can be accessed by dialling in a few minutes before the start and informing the operator that you would like to participate in Welltec’s investor conference call. Relevant dial-in details and conference ID can be obtained by contacting Kris Petrov krpetrov@welltec.com and registering for the call. Registration will not be possible once the investor conference has started. The Q3 2024 Interim Report will be made available in the “Investor Room” on Welltec’s website at https://www.welltec.com/discover/investors. For...

HII Names Steve Powell as Corporate Vice President and Treasurer

Written by Customer Service on September 20, 2024. Posted in Public Companies.

NEWPORT NEWS, Va., Sept. 20, 2024 (GLOBE NEWSWIRE) — Global all-domain defense provider HII (NYSE: HII) announced today that Steve Powell, HII’s assistant treasurer for banking and capital markets, will become the company’s next corporate vice president and treasurer, effective Jan. 1, 2025. Powell will succeed D.R. “Rick” Wyatt, who will retire at the end of this year after more than four decades of service with the company. In this role, Powell will be responsible for banking and credit, corporate finance, cash management and forecasting, insurance and risk management, M&A valuation and financing, investments and trusts, capital structure, capital markets, rating agency relationships, short-term investments, and pension trust asset management. Powell will report directly to Executive Vice President and Chief Financial Officer...

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Written by Customer Service on September 20, 2024. Posted in Public Companies.

PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group” or the “Company“) (CSE: PSYG) (as seller), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that it has entered into a conditional share sale agreement with its NASDAQ-listed associate, Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or “PBM“) (as purchaser) for the disposal by Psyence Group of its 11.13% stake in privately-held PsyLabs, a company focused on the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug...

ChemoMetec makes offer to buy Ovizio Imaging Systems SA

Written by Customer Service on September 20, 2024. Posted in Public Companies.

ANNOUNCEMENT NO. 276 20 September 2024 ChemoMetec makes offer to buy Ovizio Imaging Systems SA ChemoMetec has submitted an indicative offer to buy Belgian company Ovizio Imaging Systems (‘Ovizio’), which has been accepted by the company’s group of owners. ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. Ovizio has developed a cell counter based on holographic microscopy. The instrument is primarily used in bioprocessing and in cell and gene therapy. Ovizio’s product is connected directly to the customers’ bioreactors via a disposable item, which is supplied sterilised and with a high degree of cleanness. With the cell counter, cells can be continuously extracted from the bioreactor for analysis and subsequently returned to the...

Day: September 20, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice